Covalon Technologies Ltd. (CVALF)
USD 2.42
(-1.63%)
USD 2.42
(-1.63%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 24.9 Million CAD | -18.03% |
| 2022 | 30.37 Million CAD | -25.14% |
| 2021 | 40.58 Million CAD | 16.96% |
| 2020 | 34.69 Million CAD | -12.4% |
| 2019 | 39.6 Million CAD | 100.97% |
| 2018 | 19.7 Million CAD | 64.68% |
| 2017 | 11.96 Million CAD | 84.43% |
| 2016 | 6.48 Million CAD | -14.96% |
| 2015 | 7.63 Million CAD | -4.15% |
| 2014 | 7.96 Million CAD | 40.41% |
| 2013 | 5.67 Million CAD | -4.92% |
| 2012 | 5.96 Million CAD | -36.03% |
| 2011 | 9.32 Million CAD | -9.67% |
| 2010 | 10.31 Million CAD | -19.8% |
| 2009 | 12.86 Million CAD | -25.59% |
| 2008 | 17.29 Million CAD | -14.58% |
| 2007 | 20.24 Million CAD | 130.22% |
| 2006 | 8.79 Million CAD | 95.39% |
| 2005 | 4.5 Million CAD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | 22.28 Million CAD | -10.5% |
| 2024 Q3 | 26.52 Million CAD | 13.9% |
| 2024 Q2 | 23.28 Million CAD | 4.5% |
| 2023 FY | 24.9 Million CAD | -18.03% |
| 2023 Q1 | 30.01 Million CAD | -1.21% |
| 2023 Q2 | 27.92 Million CAD | -6.96% |
| 2023 Q4 | 24.9 Million CAD | -5.84% |
| 2023 Q3 | 26.44 Million CAD | -5.29% |
| 2022 FY | 30.37 Million CAD | -25.14% |
| 2022 Q3 | 32.02 Million CAD | -7.35% |
| 2022 Q1 | 37.56 Million CAD | -7.43% |
| 2022 Q4 | 30.37 Million CAD | -5.14% |
| 2022 Q2 | 34.56 Million CAD | -7.99% |
| 2021 Q4 | 40.58 Million CAD | 21.23% |
| 2021 Q1 | 32.15 Million CAD | -7.33% |
| 2021 Q3 | 33.47 Million CAD | 0.84% |
| 2021 FY | 40.58 Million CAD | 16.96% |
| 2021 Q2 | 33.19 Million CAD | 3.24% |
| 2020 Q4 | 34.69 Million CAD | -9.63% |
| 2020 Q2 | 38.72 Million CAD | -1.41% |
| 2020 Q3 | 38.39 Million CAD | -0.86% |
| 2020 FY | 34.69 Million CAD | -12.4% |
| 2020 Q1 | 39.27 Million CAD | -0.83% |
| 2019 Q2 | 38.43 Million CAD | 0.41% |
| 2019 Q4 | 39.6 Million CAD | 16.09% |
| 2019 FY | 39.6 Million CAD | 100.97% |
| 2019 Q1 | 38.28 Million CAD | 94.25% |
| 2019 Q3 | 34.11 Million CAD | -11.24% |
| 2018 Q1 | 13.04 Million CAD | 9.0% |
| 2018 Q4 | 19.7 Million CAD | 21.8% |
| 2018 FY | 19.7 Million CAD | 64.68% |
| 2018 Q2 | 13.22 Million CAD | 1.41% |
| 2018 Q3 | 16.18 Million CAD | 22.32% |
| 2017 Q3 | 11.49 Million CAD | 40.24% |
| 2017 Q2 | 8.19 Million CAD | 16.72% |
| 2017 Q4 | 11.96 Million CAD | 4.08% |
| 2017 FY | 11.96 Million CAD | 84.43% |
| 2017 Q1 | 7.02 Million CAD | 8.25% |
| 2016 Q3 | 7.65 Million CAD | -5.01% |
| 2016 Q1 | 8.65 Million CAD | 13.48% |
| 2016 FY | 6.48 Million CAD | -14.96% |
| 2016 Q4 | 6.48 Million CAD | -15.27% |
| 2016 Q2 | 8.06 Million CAD | -6.9% |
| 2015 Q4 | 7.63 Million CAD | -8.11% |
| 2015 FY | 7.63 Million CAD | -4.15% |
| 2015 Q3 | 8.3 Million CAD | -2.68% |
| 2015 Q2 | 8.53 Million CAD | 6.45% |
| 2015 Q1 | 8.01 Million CAD | 0.69% |
| 2014 FY | 7.96 Million CAD | 40.41% |
| 2014 Q1 | 9.19 Million CAD | 62.19% |
| 2014 Q3 | 9.17 Million CAD | -3.08% |
| 2014 Q2 | 9.46 Million CAD | 2.95% |
| 2014 Q4 | 7.96 Million CAD | -13.25% |
| 2013 Q4 | 5.67 Million CAD | 3.1% |
| 2013 Q2 | 5.04 Million CAD | -4.93% |
| 2013 Q1 | 5.3 Million CAD | -11.05% |
| 2013 FY | 5.67 Million CAD | -4.92% |
| 2013 Q3 | 5.49 Million CAD | 9.05% |
| 2012 Q2 | 8.09 Million CAD | -5.6% |
| 2012 Q1 | 8.56 Million CAD | -8.07% |
| 2012 Q3 | 7.34 Million CAD | -9.16% |
| 2012 Q4 | 5.96 Million CAD | -18.86% |
| 2012 FY | 5.96 Million CAD | -36.03% |
| 2011 Q1 | 9.3 Million CAD | -9.81% |
| 2011 FY | 9.32 Million CAD | -9.67% |
| 2011 Q3 | 7.18 Million CAD | -12.86% |
| 2011 Q4 | 9.32 Million CAD | 29.69% |
| 2011 Q2 | 8.24 Million CAD | -11.37% |
| 2010 Q3 | 11.53 Million CAD | 10.94% |
| 2010 Q4 | 10.31 Million CAD | -10.55% |
| 2010 Q1 | 12.38 Million CAD | -3.74% |
| 2010 Q2 | 10.39 Million CAD | -16.04% |
| 2010 FY | 10.31 Million CAD | -19.8% |
| 2009 Q3 | 13.73 Million CAD | -9.32% |
| 2009 Q2 | 15.14 Million CAD | -7.86% |
| 2009 Q4 | 12.86 Million CAD | -6.33% |
| 2009 FY | 12.86 Million CAD | -25.59% |
| 2009 Q1 | 16.44 Million CAD | -4.92% |
| 2008 Q2 | 18.72 Million CAD | -3.99% |
| 2008 Q1 | 19.5 Million CAD | -3.64% |
| 2008 Q4 | 17.29 Million CAD | -6.29% |
| 2008 FY | 17.29 Million CAD | -14.58% |
| 2008 Q3 | 18.45 Million CAD | -1.47% |
| 2007 FY | 20.24 Million CAD | 130.22% |
| 2007 Q2 | 10.38 Million CAD | 21.39% |
| 2007 Q3 | 11.41 Million CAD | 9.9% |
| 2007 Q4 | 20.24 Million CAD | 77.41% |
| 2007 Q1 | 8.55 Million CAD | -2.72% |
| 2006 Q4 | 8.79 Million CAD | -5.7% |
| 2006 FY | 8.79 Million CAD | 95.39% |
| 2006 Q1 | 4.23 Million CAD | -5.91% |
| 2006 Q2 | 9.72 Million CAD | 129.65% |
| 2006 Q3 | 9.32 Million CAD | -4.1% |
| 2005 Q3 | 4.72 Million CAD | -4.82% |
| 2005 FY | 4.5 Million CAD | 0.0% |
| 2005 Q1 | 4.29 Million CAD | 0.0% |
| 2005 Q4 | 4.5 Million CAD | -4.66% |
| 2005 Q2 | 4.95 Million CAD | 15.4% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | 38.84 Million USD | 35.901% |
| Nanobac Pharmaceuticals, Incorporated | 7.21 Million USD | -244.895% |
| SQZ Biotechnologies Company | 107.18 Million USD | 76.769% |
| Evofem Biosciences, Inc. | 10.55 Million USD | -135.935% |
| Santhera Pharmaceuticals Holding AG | 130.21 Million USD | 80.877% |
| Mesoblast Limited | 667.9 Million USD | 96.272% |
| Propanc Biopharma, Inc. | 72.36 Thousand USD | -34309.719% |
| Genus plc | 1.02 Billion USD | 97.58% |
| VioQuest Pharmaceuticals, Inc. | 1.35 Million USD | -1733.146% |
| CNBX Pharmaceuticals Inc. | 499.03 Thousand USD | -4889.709% |
| Marizyme, Inc. | 22.01 Million USD | -13.107% |
| ContraFect Corporation | 20.67 Million USD | -20.415% |
| Nymox Pharmaceutical Corporation | 627 Thousand USD | -3871.386% |
| PsyBio Therapeutics Corp. | 390.36 Thousand USD | -6278.781% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 382.17 Thousand USD | -6415.461% |
| Intellipharmaceutics International Inc. | 1.43 Million USD | -1638.829% |
| AXIM Biotechnologies, Inc. | 4.14 Million USD | -500.59% |
| MultiCell Technologies, Inc. | 126.22 USD | -19727829.805% |
| Accustem Sciences Inc. | 939.68 Thousand USD | -2549.876% |
| RVL Pharmaceuticals plc | 128.51 Million USD | 80.624% |
| EV Biologics, Inc. | 431.71 Thousand USD | -5667.845% |
| Q BioMed Inc. | 3.51 Million USD | -608.305% |
| Emmaus Life Sciences, Inc. | 35.17 Million USD | 29.217% |
| Neon Bloom, Inc. | 770.64 Thousand USD | -3131.141% |
| Mosaic ImmunoEngineering Inc. | 261.27 Thousand USD | -9430.343% |
| Biomind Labs Inc. | 73.81 Thousand USD | -33631.957% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Pharming Group N.V. | 462.85 Million USD | 94.62% |
| Oncotelic Therapeutics, Inc. | 30.01 Million USD | 17.039% |
| Skye Bioscience, Inc. | 11.94 Million USD | -108.541% |
| Therapeutic Solutions International, Inc. | 3.31 Million USD | -651.6% |
| THC Farmaceuticals, Inc. | 2.74 Million USD | -806.684% |
| Arch Therapeutics, Inc. | 1.95 Million USD | -1171.613% |
| IMV Inc. | 31.33 Million USD | 20.531% |
| Acro Biomedical Co., Ltd. | 687.48 Thousand USD | -3521.978% |
| Curative Biotechnology, Inc. | 2.6 Million USD | -856.539% |
| GB Sciences, Inc. | 103.44 Thousand USD | -23972.034% |
| Alpha Cognition Inc. | 2.45 Million USD | -915.451% |
| HST Global, Inc. | 1526.00 USD | -1631655.767% |
| CSL Limited | 38.02 Billion USD | 99.935% |
| Halberd Corporation | 10.13 Thousand USD | -245686.132% |
| Enzolytics Inc. | 361.7 Million USD | 93.116% |
| Resverlogix Corp. | 8.11 Million USD | -206.846% |
| Affymax, Inc. | 7.44 Million USD | -234.55% |
| SYBLEU INC | 330.46 Thousand USD | -7434.948% |
| Nuo Therapeutics, Inc. | 1.87 Million USD | -1225.995% |
| argenx SE | 4.54 Billion USD | 99.452% |
| MetaStat, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | 27.94 Million USD | 10.891% |
| Enzon Pharmaceuticals, Inc. | 47.7 Million USD | 47.8% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| RespireRx Pharmaceuticals Inc. | 22.78 Thousand USD | -109204.214% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 8.94 Million USD | -178.245% |
| AVAX Technologies, Inc. | 7.37 Million USD | -237.536% |
| Zenith Capital Corp. | 7410.00 USD | -335940.391% |
| Genscript Biotech Corporation | 3.38 Billion USD | 99.265% |
| Ember Therapeutics, Inc. | 184.00 USD | -13532830.978% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 321.8 Thousand USD | -7637.765% |
| WPD Pharmaceuticals Inc. | 261.36 Thousand USD | -9427.17% |
| American Oriental Bioengineering, Inc. | 446.3 Million USD | 94.421% |
| Provectus Biopharmaceuticals, Inc. | 1.44 Million USD | -1618.654% |
| Adynxx, Inc. | - USD | -Infinity% |
| Helix BioMedix, Inc. | 3.02 Million USD | -723.137% |
| GlobeStar Therapeutics Corporation | - USD | -Infinity% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 52.7 Million USD | 52.751% |
| Cotinga Pharmaceuticals Inc. | 927.96 Thousand USD | -2583.366% |
| BioStem Technologies, Inc. | 14.56 Million USD | -71.017% |
| ONE Bio Corp. | 70.08 Million USD | 64.471% |
| Reve Technologies, Inc. | 57.09 Thousand USD | -43513.327% |
| Burzynski Research Institute, Inc. | 2310.00 USD | -1077847.749% |
| Wesana Health Holdings Inc. | 987.96 Thousand USD | -2420.387% |
| Agentix Corp. | 261.39 Thousand USD | -9426.15% |
| LadRx Corporation | 2.3 Million USD | -978.937% |
| Cell Source, Inc. | 195.17 Thousand USD | -12658.347% |
| ProtoKinetix, Incorporated | 480.55 Thousand USD | -5081.611% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | -6941.684% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | -6941.684% |
| NovAccess Global Inc. | 62.24 Thousand USD | -39902.238% |
| Endonovo Therapeutics, Inc. | 639.65 Thousand USD | -3792.81% |
| Itoco Inc. | 1.4 Million USD | -1678.522% |
| Rasna Therapeutics, Inc. | 95.65 Thousand USD | -25931.125% |
| Pathfinder Cell Therapy, Inc. | 106 Thousand USD | -23391.125% |
| Kadimastem Ltd | 2.3 Million USD | -980.717% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Institute of Biomedical Research Corp. | 76.35 Thousand USD | -32512.035% |
| CytoDyn Inc. | 11.13 Million USD | -123.604% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 142.97 Thousand USD | -17316.412% |
| Mobile Lads Corp. | 52.00 USD | -47885655.769% |
| NanoSphere Health Sciences Inc. | 17.88 Thousand USD | -139165.062% |
| Qrons Inc. | 420.00 USD | -5928612.619% |
| Alseres Pharmaceuticals, Inc. | 385.47 Thousand USD | -6359.784% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 552.12 Thousand USD | -4409.997% |
| Rebus Holdings, Inc. | 5000.00 USD | -497911.86% |
| ImmunoCellular Therapeutics, Ltd. | 409.42 Thousand USD | -5981.889% |
| International Stem Cell Corporation | 5.39 Million USD | -361.978% |
| Bioxytran, Inc. | 137.63 Thousand USD | -17991.365% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 15 Million USD | -65.984% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | - USD | -Infinity% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 16.57 Million USD | -50.194% |
| Adhera Therapeutics, Inc. | 79 Thousand USD | -31419.738% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 864.67 Thousand USD | -2779.757% |
| Innovation Pharmaceuticals Inc. | 7.51 Million USD | -231.257% |
| Neutra Corp. | 2851.00 USD | -873298.562% |
| Windtree Therapeutics, Inc. | 32.4 Million USD | 23.161% |
| PureTech Health plc | 693.97 Million USD | 96.412% |
| Coeptis Therapeutics, Inc. | 8.07 Million USD | -208.516% |
| IXICO plc | 15.84 Million USD | -57.162% |
| IntelGenx Technologies Corp. | 8.28 Million USD | -200.659% |
| Gelesis Holdings, Inc. | 103.32 Million USD | 75.9% |
| CSL Limited | 38.02 Billion USD | 99.935% |
| Cellectis S.A. | 333.99 Million USD | 92.545% |